HArmonyCa with Lidocaine is a hybrid dermal filler combining cross-linked hyaluronic acid (HA) with calcium hydroxyapatite (CaHA) to deliver both immediate volumization and long-term collagen stimulation.This dual-action formulation provides structural lift, contour refinement, and gradual improvement of skin quality over time.
The HA component offers instant smoothing and hydration, while CaHA particles promote neocollagenesis, enhancing firmness and elasticity in the months following treatment.HArmonyCa is particularly effective for the midface, lateral cheeks, jawline, and other areas requiring lift without excessive projection.Results typically last 18-24 months, depending on anatomical area, technique, and patient metabolism.
Rheological properties / Product data
HA concentration: Cross-linked hyaluronic acid base
Texture: Hybrid monophasic HA gel with suspended CaHA particles
Lift capacity (G′): High
Cohesivity: High
Lidocaine content: 0.3%
Volume per syringe: 1.25 ml
Packaging: 2 prefilled syringes
Injection depth & tools
Recommended depth: Deep dermis or subdermal / supraperiosteal plane
Injection techniques:
Retrograde linear threading
Micro-bolus technique
Deep structural support points
Recommended instruments:
27G needle
25G cannula (optional for advanced contouring)
Avoid superficial injection due to CaHA content.Aspirate before injecting; proceed slowly to minimize intravascular risk.Use only by practitioners trained in hybrid fillers.
Storage & handling
Store at 2 °C - 25 °C, protected from heat and direct light
Do not freeze
Single-use only - discard after opening
Do not massage aggressively post-injection
Dispose of needles, syringes, and unused material according to medical waste guidelines
Intended for use by licensed medical professionals only.
Alcohol consumption should be avoided 24 hours before and after the procedure to reduce vasodilation, bruising, and inflammation risk.
Contraindicated during pregnancy. No clinical safety data are available; elective aesthetic procedures should be postponed until after childbirth.
Not recommended while breastfeeding due to insufficient evidence on metabolite excretion through breast milk. Procedures should be deferred until breastfeeding is completed.
Inject into the subdermal to deep dermal layers using linear threading or micro-bolus technique according to the anatomical area. Always aspirate before injection, proceed slowly, and avoid high-risk vascular zones. The procedure should be performed under strict aseptic conditions by trained practitioners.
Expected mild reactions include redness, tenderness, swelling, or bruising at the injection site, typically resolving within several days. Rare but serious adverse events — such as vascular occlusion or inflammatory nodules — require immediate medical attention. Patients should avoid touching or massaging treated areas and refrain from heat exposure for 24–48 hours.
The cross-linked hyaluronic acid provides immediate volumization and hydration, while CaHA microspheres serve as a biostimulatory scaffold, inducing neocollagenesis and improving dermal density over time. The combination delivers both instant lift and progressive skin remodeling.
Cross-linked Hyaluronic Acid (HA) and Calcium Hydroxylapatite (CaHA) microspheres in a cohesive gel matrix, with Lidocaine (0.3%) for pain reduction.
